

PRESS RELEASE

29 November 2024 08:00:00 CET

Saniona presents at Redeye Technology & Life Science Day

Saniona participates in Redeye Technology & Life Science Day on December 3 with a presentation by CEO Thomas Feldthus and CSO Karin Sandager Nielsen.

The presentation highlights the recently signed license agreement for SAN711 with Acadia, Saniona's strategy and the next step forward for the company. Karin Sandager Nielsen presents SAN2465, which has potential for the treatment of patients with MDD (major depressive disorder) and the rare disease Dup15q.

Saniona's presentation takes place at 3.20 pm (CET), Stream 2.

Link to the event: <https://www.redeye.se/events/1038747/redeye-technology-life-science-day>

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline includes SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona's most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona presents at Redeye Technology & Life Science Day